Optimizing Quality Assurance in a Prospective Phase II Clinical Trial for Intermediate-Risk Prostate Cancer with Brachytherapy as Monotherapy Using a Paladium -103 Standed-Seed Nomogram
Byline
R Kudchadker*, T Pugh, T Bruno, W Du, D Swanson, S Frank, UT MD Anderson Cancer Center, Houston, TX